Merck’s plan to introduce a subcutaneous formulation of Keytruda in Germany has been halted after a Munich court issued a preliminary injunction siding with Halozyme’s patent infringement claims.
Pacira has sued WhiteOak and Qilu after ANDA filings for generic EXPAREL, initiating a 30-month FDA stay and strengthening its defense of 21 Orange Book patents.
The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Metsera’s board has deemed Novo Nordisk’s $10 billion bid superior to Pfizer’s, setting off a high-stakes bidding and legal battle amid the obesity-drug gold rush.
Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.